Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Functional outcome improvements with atogepant sustained until 3 years
15 Jul 2026
bởiAudrey Abella
A 156-week safety extension study presented at EAN 2026 shows the first 3-year long-term results for atogepant in the preventive treatment of migraine in individuals with chronic migraine (CM) or episodic migraine (EM) who had an insufficient response to 2–4 classes of conventional oral, non-migraine-specific preventive migraine treatments.








